Cue Biopharma Inc (NASDAQ:CUE) Expected to Announce Earnings of -$0.41 Per Share
Brokerages expect Cue Biopharma Inc (NASDAQ:CUE) to announce ($0.41) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cue Biopharma’s earnings, with estimates ranging from ($0.46) to ($0.30). Cue Biopharma posted earnings of ($0.46) per share in the same quarter last year, which would suggest a positive year over year growth rate of 10.9%. The firm is scheduled to announce its next earnings results on Thursday, August 13th.
According to Zacks, analysts expect that Cue Biopharma will report full year earnings of ($1.64) per share for the current year, with EPS estimates ranging from ($1.89) to ($1.33). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.64) per share, with EPS estimates ranging from ($1.82) to ($1.33). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Cue Biopharma.
Cue Biopharma (NASDAQ:CUE) last released its earnings results on Tuesday, May 19th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Cue Biopharma had a negative return on equity of 103.99% and a negative net margin of 959.08%.
Cue Biopharma stock opened at $18.91 on Tuesday. Cue Biopharma has a 52 week low of $6.95 and a 52 week high of $31.69. The stock has a fifty day moving average of $23.20 and a 200-day moving average of $20.43.
In other Cue Biopharma news, Director Aaron G.L. Fletcher purchased 7,500 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was purchased at an average cost of $24.88 per share, for a total transaction of $186,600.00. Following the transaction, the director now owns 155,499 shares in the company, valued at approximately $3,868,815.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 9.50% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Corriente Advisors LLC lifted its position in shares of Cue Biopharma by 187.7% in the 1st quarter. Corriente Advisors LLC now owns 820,000 shares of the company’s stock worth $11,636,000 after purchasing an additional 535,000 shares during the period. Prosight Management LP raised its stake in Cue Biopharma by 301.1% during the first quarter. Prosight Management LP now owns 552,060 shares of the company’s stock worth $7,834,000 after buying an additional 414,432 shares during the last quarter. Ghost Tree Capital LLC acquired a new position in Cue Biopharma in the first quarter valued at $1,774,000. Federated Hermes Inc. lifted its holdings in Cue Biopharma by 693.5% in the first quarter. Federated Hermes Inc. now owns 86,986 shares of the company’s stock valued at $1,234,000 after buying an additional 76,024 shares during the period. Finally, Nuveen Asset Management LLC boosted its position in Cue Biopharma by 86.9% during the fourth quarter. Nuveen Asset Management LLC now owns 130,779 shares of the company’s stock valued at $2,077,000 after acquiring an additional 60,825 shares during the last quarter. 45.95% of the stock is currently owned by hedge funds and other institutional investors.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Further Reading: What member countries make up the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.